Professor kojuri cardiology clinic
Shiraz, Outside of the US, 55318, Iran
NCT Number: NCT04923152
In this study post coronary stenting patients, were enrolled to receive moderate dose versus high dose statin for 1 year, and the result of major adverse cardiovascular events were recorded
Looking for future studies?
Notify Me52 year–75 year
All sexes
Interventional
Not applicable
Shiraz, Outside of the US, 55318, Iran
In this randomized double-blind clinical trial, the study population was all patients with a recent history of PCI who referred to the professor kojuri cardiovascular clinic for the first post-procedure visit. In the first visit, patients were randomly divided into two groups Both groups were treated with Rosuvastatin 40 mg as high potency statin for one month after PCI. In the first group, after one month, the statin level changed to Rosuvastatin 5 mg daily (moderate intensity). In the second group, 40 mg of Rosuvastatin was continued for one year. Then, the participants were evaluated in terms of MACEs, including any hospitalization due to acute coronary syndrome, as well as history of stroke and myocardial Infarction, subsequent unplanned revascularization and cardiac death. The HS-CRP also checked between two groups
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
5 mg rosuvastatin per day
40 mg rosuvastatin per day
Time frame: 1 year
major adverse cardiovascular events
Time frame: 1 year
Shiraz University of Medical Sciences
Other
Effects of High- or Moderate-Dose Statin on 1-Year Major Adverse Cardiovascular Events (MACE) Post Percutaneous Coronary Interventions
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04465669
Angina Pectoris, Angina, Stable
Tyumen, Russia
View Trial DetailsNCT04938661
Acute Coronary Syndrome, Acute Myocardial Infarction
Minneapolis, Minnesota, United States
View Trial DetailsNCT06571370
Angina Pectoris, Angina, Stable
Monroe, North Carolina, United States
View Trial DetailsNCT07378228
Angina Pectoris, Angina, Stable
Harbin, Heilongjiang, China
View Trial Details